Resources

WuXi Advanced Therapies has added Mycoplasma Real-Time PCR Detection (MycoSEQ™) to our menu of innovative solutions

WuXi Advanced Therapies has added Mycoplasma Real-Time PCR Detection (MycoSEQ™) to our menu of innovative solutions! This assay method can be used for lot release by drugmakers of biotherapeutics, cell therapy products, biologics, and vaccines to detects more than 90 mycoplasma species with high specificity and no cross-reactivity to closely-related bacterial species rapidly and reliably. …Read More >

Resource Type: Publication
Resource Topic: Advanced Testing

VIEW

3 business challenges from the CDMO’s perspective

Felix Hsu, SVP and Global Head of WuXi Advanced Therapies and Erin Harris, Editor in Chief for Cell & Gene had a great conversation around the CDMOs perspective on manufacturing. Click to learn more about 3 Business Challenges from the CDMO’s Perspective. By Erin Harris, Editor-in-Chief of cellandgene.com Copyright © 1996-2019 VertMarkets, Inc. All Rights Reserved.

Resource Type: Publication
Resource Topic: Clinical & Commercial Manufacturing

VIEW

Validation of a PCR method for the detection of mycoplasmas according to European Pharmacopoeia section 2.6.7

Recent publication of a revised section for mycoplasma testing in the European Pharmacopoeia [1] has led to interest in validating a nucleic acid amplification technique (NAT) for use in detection of mycoplasma contaminants in biologics drugs. The replacement by or supplementation of the existing culture-based methods with a PCR-based method has several advantages for the …Read More >

Resource Type: Publication
Resource Topic: Advanced Testing

VIEW